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It was previously shown that spleen cells from endogenous ecotropic murine leukemia virus emv-14+ AKXL-
5 mice fail to stimulate an anti-AKR/Gross virus cytolytic T-lymphocyte (CTL) response in a mixed lymphocyte
culture with primed C57BL/6 responder spleen cells, whereas spleen cells from AKXL strains carrying the very
similar emv-11 provirus do stimulate a response (Green and Graziano, Immunogenetics 23:106-110, 1986). We
wished to determine whether the lack of response with AKXL-5 spleen cells was at the level of recognition
between effector cell and target cell and whether the relevant mutation was within the emv-14 provirus. It is
shown here that EMV-negative SC-1 fibroblast cells transfected with the major histocompatibility complex
class I Kb gene and infected with virus isolated from the AKXL-5 strain (SC.Kb/5 cells) were not lysed by H-2b_
restricted anti-AKR/Gross virus CTL. SC.Kb cells infected with virus isolated from emv-11 strains, however,
were efficiently lysed by anti-AKR/Gross virus CTL, indicating that there is nothing intrinsic to EMV-infected
SC.Kb cells that would prevent them from being recognized and lysed efficiently by anti-AKR/Gross virus CTL.
Analysis of virus expression for the infected SC.Kb cells by XC plaque assay and by flow cytometry indicated
that emv-14 virus expression for SC.Kb/5 cells was not significantly different from that for emv-11-containing
SC.Kb/9 or SC.Kb/21 cells. These data show that the mutation responsible for the lack of CTL recognition and
lysis is at the level of recognition between target cell and effector cell. Furthermore, these data strongly suggest
that the mutation is within the emv-14 genome. Flow cytometry experiments with monoclonal antibodies against
a number of viral determinants indicated that there was no gross mutation detectable in the viral determinants
analyzed. The data suggest that the relevant mutation may be a point mutation or a small insertion or deletion
within a coding sequence that is critical for CTL recognition.
Endogenous ecotropic murine leukemia viruses (EMVs)
are present in the highly leukemia-susceptible AKR strain of
mouse and are passed on to succeeding generations through
the germ line. EMVs recombine with other endogenous
murine leukemia virus sequences to form the mink cell
focus-inducing (MCF) virus, which is thought to be directly
responsible for the high incidence of leukemia in AKR mice
(27, 31). The importance of EMV in the disease process is
underscored by the correlation of high EMV titers in new-
born mice with an increased incidence of leukemia (37). In
addition, EMV proviruses have been associated with malig-
nant lymphoma (47).
EMV proviruses are distinguished from each other by
their characteristic integration sites in the AKR genome. The
sizes of the different AKR EMV integrants are conserved, as
shown by restriction endonuclease site mapping with PstI,
which cleaves within the long terminal repeats (LTRs),
giving an 8.2-kilobase (kb) fragment (8, 59). Certain internal
restriction sites within the different integrants are also con-
served (29). The endogenous EMV proviruses found in
AKR/J mice (emv-JJ, emv-13, and emv-14) independently
segregate from each other in the AKXL (AKR/J and C57L
progenitor strains) recombinant inbred strains of mice (59).
The use of these AKXL strains allowed Green and Graziano
(21) to determine that, of these three proviruses, only emv-11
was capable of stimulating an anti-AKR/Gross virus cyto-
lytic T-lymphocyte (CTL) response. Irradiated splenic stim-
ulator cells from emv-1J-positive AKXL mice served as a
* Corresponding author.
source of viral antigen in secondary in vitro mixed lympho-
cyte cultures to induce the generation of spleen cells from
tumor-primed C57BL/6 responder mice. Spleen cells from
AKXL mice that inherited either the emv-13 or emv-14
provirus were unable to stimulate an anti-AKRIGross virus
response, however. The failure of emv-13+ spleen cells to
stimulate a response is expected, since emv-13 is known to
code for a defective virus (9), and mice that have inherited
only emv-13 are not viremic (59). The failure of emv-14 to
stimulate a response occurs despite the fact that emv-JJ-
emv-14+ AKXL-5 mice develop viremia (59; confirmed and
quantitated here), indicating that the virus must be replica-
tion competent, transcriptionally functional, and able to
form budding particles with functional envelope antigens
which allow the infection to spread laterally. This failure to
stimulate a response is surprising in light of the notion that
emv-14 was derived by reintegration of an infectious primor-
dial emv-JJ provirus (59).
One possible explanation for the failure of emv-14+ spleen
cells to stimulate anti-AKR/Gross virus CTL is that there is
a coding sequence mutation within the viral genome at a site
critical for CTL recognition, within the gp7O envelope gene,
for example. A coding sequence mutation could allow emv-
14-positive tumor cells to avoid lysis by, and prevent clonal
expansion of, antiviral CTL. This would represent one
mechanism by which tumors may escape cellular immunity
and become established. There is suggestive evidence that
the gp7O envelope antigen is a major determinant for anti-
AKR/Gross virus CTL (16, 20, 40). Other loci within the
murine genome, such as the Fv-1 locus (18, 43) and the H-2
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locus (19, 35-37, 43), can also influence the development of
antiviral immunity, however. In addition, the site of integra-
tion of provirus within the murine genome may influence
CTL activity against viral antigens, by modulating the
expression of viral antigens, for example. Prior to the
present study, it was unknown whether the mutation respon-
sible for the failure of emv-14+ cells to stimulate antiviral
CTL was within the proviral genome. It was also unknown
whether the failure of emv-14+ spleen cells to stimulate
anti-AKR/Gross virus CTL was due to a defect at the level of
recognition between the target cell and effector cell rather
than at some prior step in the CTL stimulation process such
as at the level of T-helper function.
In this study we show that when virus is isolated from
emv-11+ emv-14- AKXL-21 mice and used to infect the
virus-negative SC-1 fibroblast cell line transfected with the
H-2Kb gene (SC.Kb cells), the infected SC.Kb/21 cells are
efficient targets for H-2b-restricted anti-AKR/Gross virus
CTL. Yet SC.Kb cells infected with virus from emv-11-
emv-14+ AKXL-5 mice (SC.KbI5) cannot be lysed by anti-
AKRIGross virus CTL. These results indicate that the
mutation responsible for the lack of CTL recognition and
lysis is at the level of recognition between target cell and
effector cell and furthermore that the mutation is almost
certainly within the emv-14 genome.
MATERIALS AND METHODS
Cells and strains. The SC-1 cell line is a continuous cell
line from a wild mouse embryo (26). XC cells are a contin-
uous line from a Wistar rat tumor induced with the Prague
strain of Rous sarcoma virus and were originally obtained
from Jan Svoboda. SC-1 and XC cells were cultured in
Dulbecco modified Eagle medium supplemented with 5%
fetal bovine serum, 2 mM L-glutamine, 30 ,ug of penicillin per
ml, and 20 ,ug of streptomycin per ml. B.GV (53) and EdG2
(22) are H-2b Gross virus cell surface antigen (GCSA)-
positive tumor cell lines derived from a BALB.B congenic
mouse tumor and a C57BL/6 tumor, respectively, both
induced with AKRIGross virus passage A. AKR.H-2b SL1
(SL1) and AKR.H-2b SLi clone 18-5 (cl.18-5) are GCSA+
tumor cell lines derived from a spontaneous leukemia from
an AKR.H-2b congenic mouse (16, 22). AKR SL8 (SL8) is a
GCSA+ H-2k tumor cell line derived from a spontaneous
leukemia from an AKR/J mouse (15). YAC-1 (YAC) is an
H-2a tumor cell line that is used here as a highly natural killer
cell (NK)-sensitive target cell and as an H-2 haplotype-
specific control for anti-H-2b allogeneic CTL. All tumor cell
lines (B.GV, EdG2, SLi, cl.18-5, SL8, and YAC) were
grown in RPMI supplemented with 5% fetal bovine serum, 2
mM L-glutamine, 30 ,ug of penicillin per ml, and 20 ,ug of
streptomycin per ml. All cells were maintained at 37°C in a
5% CO2 atmosphere.
AKXL strains of mice, described by Steffen et al. (59),
were obtained from Jackson Laboratories and have the
following endogenous EMV genotypes: AKXL-5, emv-14;
AKXL-9, emv-11,13; AKXL-16, emv-11,13; AKXL-21,
emv-JJ; AKXL-28, emv-13; AKXL-29, emv-11-,13-,14-.
The EMV nomenclature has been used throughout this
paper, replacing the older AKV nomenclature as follows:
emv-JJ (akv-J), emv-13 (akv-3), and emv-14 (akv4) (29).
RNA blot analysis. Total cellular RNA was isolated by the
guanidinium-cesium chloride method (39), and 10 to 30 ,ug
was blotted onto a nitrocellulose membrane by the manufac-
turer's recommended method (Schleicher & Schuell). The
RNA blots were hybridized at 65°C overnight in a standard
hybridization medium (4x SSCP [39], ix Denhardt solution
0.1% [wt/vol] sodium dodecyl sulfate [SDS], 100 ,ug of
denatured salmon sperm DNA per ml) (29). The emv probe
used was derived from the gp7O region, a 334-base-pair (bp)
SmaI fragment, from the AKR 623 env gene cloned into the
EcoRI site of pBR322 (8, 28). This plasmid was constructed
by D. R. Lowy and S. K. Chattopadhyay and was gener-
ously provided through B. A. Taylor. Only ecotropic DNA
sequences and not xenotropic, amphotropic, or MCF murine
leukemia viruses hybridize with this probe (8). We excised
from this plasmid a 1,115-bp PstI-HindIII fragment, contain-
ing the gp7O sequence, for radiolabeling by the random
primer extension method (10). After hybridizations, the
membranes were washed at 65°C for 30 min in each of the
following conditions: ix SSCP-0.1% SDS, 0.5x SSCP-
0.1% SDS, and 0.1x SSCP-0.1% SDS. The washed filters
were then exposed to X-ray film for autoradiography.
Virus isolation and quantitation by the XC plaque assay.
Viruses were obtained from mouse tails in an alundum
suspension, and the supernatant fractions were saved as
viral extracts at -70°C (R. Bedigian, Jackson Laboratories,
personal communication). Viral extracts from various
AKXL strains were used to infect plates of SC.Kb or SC.Db
cells. AKR 623 ("emv-1 1") virus was kindly provided by Dr.
Chattopadhyay, National Institutes of Health (38).
XC plaque assays (55; R. Bedigian, personal communica-
tion) were performed to quantitate the titers of infectious
ecotropic virus from tail extracts or cell supernatant frac-
tions. Briefly, 0.32% (wt/vol) Polybrene-treated SC-1 cells (2
x 105) were infected with virus for 5 days. On day 6, the
infected cell sheet was irradiated with 254-nm UV light to
stop cell growth. The infected monolayer was then overlaid
with 1.2 x 106 XC cells. After syncytia were allowed to form
for 3 days, the cell sheets were fixed with methanol and
stained with 2% (wt/vol) methylene blue. Plaques were
counted, and viral titers were determined.
Transfections. Major histocompatibility complex (MHC)
class I genes were transfected into SC-1 cells by a modified
version of the calcium phosphate-DNA coprecipitation pro-
tocol with 35 jig of plasmid DNA and the glycerol shock
method (13, 14). The plasmids used for the transfections
were clone I225 (3), carrying the H-2Kb and Neor genes, and
clone 1250 (69), carrying the H-2Db gene with Moloney
murine leukemia virus LTR promoter and the Neor gene.
Both clones were kindly provided by Haemisch Allen,
Gerald Waneck, and Richard Flavell at Biogen. Two days
after transfection, 0.5 mg of G418 (GIBCO) per ml was
added to the cells. One week later this medium was replaced
with medium containing 1 mg of G418 per ml, and the cells
were maintained at this concentration of drug for approxi-
mately 2 weeks and then maintained at 0.5 mg of G418 per
ml.
Antibodies. Three monoclonal antibodies specific for cer-
tain MHC class I genes were used. HB41 secretes a mono-
clonal antibody, 28-13-3S, that is reactive with H-2Kb, and
HB19 secretes a monoclonal antibody, 28-11-SS, that is
reactive with H-2Db (46). MCA169 is also reactive with
H-2Db (24, 32, 33). M1/42 is a monotypic monoclonal anti-
body with broad specificity for H-2 class I antigens except
that it does not react with Db (57, 58).
Goat anti-Rauscher virus gp7O antiserum, with broad
specificity for AKR/Gross, Friend, Moloney, and Rauscher
murine leukemia virus group-specific gp7O antigenic deter-
minants, was used for some of the viral antigen analyses. In
addition, seven monoclonal antibodies specific for epitopes
of gp7O were used. Four are ascites-derived mouse mono-
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clonal antibodies: 16D7, 16C1, 19A2, and 16E4, correspond-
ing to epitopes a, b, c, and d, respectively (60). Three are
hybridoma supernatant fractions of rat origin: 35/56, 35/299,
and 42/94, which correspond to epitopes f, g, and h, respec-
tively (50). The 43-13 (AKR-specific anti-p129'9 antigen) and
43-17 (against a glycosylated gag polyprotein associated
with emv) rat monoclonal antibodies were from concentrated
hybridoma supernatant fractions (49).
Flow cytometric analysis. Cell surface antigen expression
was measured by indirect immunofluorescence. Cells (2.5 x
105) were washed with staining medium (HEPES [N-2-
hydroxyethylpiperazine-N'-2-ethanesulfonic acid]-buffered
RPMI 1640 [GIBCO] containing 0.2% [wt/vol] bovine serum
albumin [fraction V; Sigma Chemical Co.]) and incubated
with the appropriately diluted antibody for 30 min at 4°C.
The samples were then washed twice in staining medium.
Afterwards, the appropriately diluted fluorescein isothiocy-
anate-conjugated secondary antibody (goat anti-mouse, goat
anti-rat, or swine anti-goat immunoglobulin) was added.
Normal goat preimmune serum was used as a negative
control for the goat anti-Rauscher gp7O antiserum. Back-
ground fluorescence values were determined with the follow-
ing irrelevant monoclonal antibodies used as isotype con-
trols: OKT8 (CRL 8014, mouse immunoglobulin G2a
[IgG2a]) for MCA169, 16D7, 16C1, or 16E4; HB70 (mouse
IgG3) for 19A2; 35.12 (mouse IgM, kindly provided by R. J.
Noelle at Dartmouth Medical School) for HB41 or HB19;
MAC-2 (TIB 166, rat IgG2a) for 35/56, 35/299, or 42/94; or
MAC-1 (TIB 128, rat IgG2b) for 43/13 or 43/17. The cells
were incubated at 4°C for 30 min and then washed once with
staining medium. The samples were suspended in staining
medium for flow cytometry analysis on an Ortho 50H
cytofluorograph.
Cell sorting. SC-1-derived cell populations transfected
with the Kb gene were sorted on an Ortho 50H cytofluoro-
graph to obtain a subpopulation of cells expressing high
concentrations of cell surface Kb antigen. The cells were
then maintained in G418-free medium. Similarly, SC-1 cells
transfected with the Db gene were sorted to obtain a sub-
population of cells expressing high concentrations of Db
antigen.
Cytotoxicity assays. For the generation of allogeneic CTL
directed against H-2b target cells, responder DBA/2J (H-2d)
spleen cells were mixed with irradiated (2,000 rads) C57BL/
6J (H-2b) stimulator spleen cells at a responder-to-stimulator
cell ratio of 2:1 on day 0. On day 5, fibroblast targets were
labeled with 51Cr overnight at 37°C. On day 6, tumor cells
were labeled with 51Cr as described by Green et al. (22),
splenic effector cells were harvested, and the 51Cr release
assay was performed as described by Green (17) (see below).
For the generation of anti-AKR/Gross virus CTL, C57BL/
6J mice were immunized with 2 x 106 B.GV cells. Re-
sponder spleen cells from immune mice were mixed with
irradiated (8,000 rads) SL1 stimulator cells at a responder-
to-stimulator cell ratio of 50:1. Effector cells were harvested
and incubated with 51Cr-labeled target cells at an effector-
to-target cell ratio of 100:1, 20:1, and 4:1 at 37°C (6 h for
fibroblast targets and 4 h for tumor targets).
RESULTS
RNA blot analysis of AKXL tissue. Since emv-14+ AKXL-5
spleen cells failed to stimulate anti-AKR/Gross virus CTL
with primed C57BL/6 responder cells (21), it was important
to determine whether the emv-14 provirus was transcription-
ally active in AKXL-5 tissues relative to emv- J + AKXL-21
-10 ug
- AKXL-5
-20 ug (emv 14)
-10 ug
-20 ug AKXL-21
(ernv 1 1 )
-30 ug
-10 ug I AKXL-29
(emv 11-, 14-)
FIG. 1. AKXL liver RNA blot hybridization with emv probe.
Total RNA (10, 20, or 30 ,ug, as indicated) was blotted onto a
nitrocellulose membrane and hybridized with the emv probe as
detailed in Materials and Methods. The hybridized blot was washed
under standard high-stringency conditions and exposed for 4 days to
X-ray film as described in Materials and Methods. The emv geno-
types of the strains from which the RNA was isolated are as follows:
AKXL-5, emv-14; AKXL-21, emv-J1; AKXL-29, emv-11- and
emv-14-. AKXL-29 served as a negative control for virus expres-
sion.
tissues. Total RNA was isolated from various AKXL liver or
thymus tissues, blotted onto nitrocellulose filters, and hy-
bridized with a DNA probe derived from the env gene and
specific for EMV sequences (emv probe; see Materials and
Methods). Figure 1 shows representative autoradiographic
data. The amount of AKXL-5-derived RNA that hybridized
to the emv probe was not significantly different from that
seen for AKXL-21-derived RNA. RNA from AKXL-29 or
C57L (emv-11-,13-,14-) mice was used as a negative con-
trol in these experiments. In other experiments, Northern
(RNA blot) analysis showed that the RNA transcripts were
the expected size of the genome size 8.2-kb transcript (data
not shown). The spliced env transcript was not detected in
RNA samples from either emv-14+ AKXL-5 tissue or from
emv-11+ emv-13+ AKXL-9 positive control tissue, perhaps
reflecting a low steady-state level of spliced emv message in
general. The data are consistent with the notion that emv-14
is transcribed at a level similar to that seen for emv-JJ.
Isolation and quantitation of EMV from AKXL mice. To
further explore the expression of ecotropic virus in emv-
14-positive mice relative to emv-JJ-positive mice, the rela-
tive titers of these viruses from the relevant strains ofAKXL
mice were quantitated by the XC plaque assay. Virus
isolates were obtained from AKXL strains with the follow-
ing emv genotypes: AKXL-21 (emv-JJ+), AKXL-9 (emv-ll+
emv-13+), AKXL-16 (emv-JJ+ emv-13+), AKXL-28 (emv-
13+), and AKXL-5 (emv-14+). These virus isolates were
quantitated by the XC plaque assay to determine the relative
levels of viremia in the different AKXL strains. Figure 2
shows viral titers from a representative experiment. The
viral titer from the emv-14+ AKXL-5 strain was consistently
found to be within the range of titers observed for the
emv-ll+ strains, confirming that emv-14 is antigen expres-
sion competent as well as message expression competent.
The emv-13+ AKXL-28 strain was negative for infectious
ecotropic virus, as expected, since emv-13 is known to be
replication defective (9). There is the potential for increased
viral titers in emv-11+ emv-13+ mice because the defective
emv-13 may be pseudotyped or complemented by emv-JJ (as
is known to occur for emv-3 with emv-13 [9]). Such comple-
mentation may not explain the consistently observed in-
creased virus titers and RNA expression of AKXL-9 mice,
however, since AKXL-16 mice are also emv-1J+ emv-13+
J. VIROL.
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FIG. 2. Viral titers ofAKXL mice. The viral titer of the AKXL-5
strain is compared with that of other AKXL strains by the XC
plaque assay as given in Materials and Methods. The AKXL emv
genotypes are as indicated.
but show somewhat decreased titers in comparison. Extracts
from the C57L parental strain were also found to be nega-
tive, as expected. C57L mice have been reported to be
emv-16+ emv-17+ (6) but were not viremic when assayed by
the XC plaque assay (Fig. 2), indicating that these loci do not
encode replication- and expression-competent emv. In fact,
Buchberg et al. (6) maintain that the "emv-17 allele" found
in C57L mice is not even associated with an ecotropic
provirus, but is defined on the basis of a restriction fragment
length polymorphism associated with the viral preintegration
site.
Preparation and analysis of SC.Kb cells. We wished to
determine whether sequences within the emv-14 virus were
responsible for the failure of spleen cells from emv-14+
AKXL-5 mice to stimulate anti-AKR/Gross virus CTL. Our
approach was to use virus isolates from AKXL-5 mice, and
from AKXL-21 mice (emv-JJ+) as a positive control, to
infect cells in culture and then determine whether these
infected cells function as target cells for H-2b restricted
anti-AKR/Gross virus CTL. One would predict that emv-14+
H-2b targets would fail to be lysed if the defect responsible
for the failure of AKXL-5 spleen cells to stimulate CTL were
within the emv-14 provirus and at the level of recognition
between effector and viral antigen-positive cell.
In order to infect virus isolated from AKXL mice of
various emv genotypes into cells in culture, it is important
that the recipient cells be virus negative. The use of cells,
such as L cells, that are already positive for murine leukemia
viruses can result in significant background levels of nonspe-
cific lysis in the antiviral CTL assay (2). We chose the SC-1
continuous line of wild mouse embryo cells because this line
is negative for ecotropic viruses by several criteria. When
SC-1 cells are used in the XC plaque assay for ecotropic
viruses, no plaques are formed. A broad-spectrum goat
anti-Rauscher gp7O antiserum fails to stain these cells signif-
icantly above background levels in flow cytometric analysis
(data not shown). Culture of SC-1 cells in the presence of
iododeoxyuridine (IUdR), an iodinated pyrimidine analog
known to activate latent EMV proviruses with high fre-
quency (1, 54), failed to induce viral expression as assayed
by the XC plaque assay or by flow cytometric analysis (data
not shown). Southern blot analysis with genomic DNA from
SC-1 cells digested with the restriction endonuclease BamHI
failed to show any hybridization signal with the emv probe
(data not shown). BamHI digests EMV proviruses internally
at conserved sites on both sides of the 334-bp SmaI probe
sequence, giving a characteristic 3.3-kb fragment (29). The
SC-1 cell line therefore appeared to be a good virus-negative
recipient for infection with virus isolates from various
AKXL emv genotype strains.
It was also necessary that the infected SC-1 cells be
histocompatible with the anti-AKRIGross virus CTL gener-
ated from C57BL/6 responder mice. Previously it was
shown, by examining the ability of various antibodies to
block cell-mediated lysis, that the K antigen rather than the
D antigen restricted these anti-AKR/Gross virus CTL (23).
Since SC-1 cells are derived from wild mouse embryo cells,
their H-2 haplotype was unknown to us. It was confirmed
that the SC-1 H-2 locus was not of the b haplotype. There
was no significant staining with either anti-Kb (HB41) or
anti-Db (MCA169 or HB19) monoclonal antibodies above
background levels of staining as assayed by flow cytometry
with indirect immunofluorescence (Fig. 3). In addition, the
monotypic anti-H-2 class I monoclonal antibody Ml/42,
which binds efficiently to H-2Kb and most other class I
antigens, did not bind significantly to SC-1 cells (data not
shown), indicating either that SC-1 cells have low levels of
H-2 antigens or that there is poor cross-reactivity with the
endogenous H-2 antigens found in SC-1 cells. SC-1 cells
were therefore made to be H-2Kb positive by transfection
(see Materials and Methods) with the Kb gene maintained in
the plasmid pTCF along with the Neor gene, conveying
resistance to the drug G418 (3). The bulk population of cells
that survived G418 drug selection was sorted for those
SC.Kb cells expressing the highest concentrations of Kb
antigen on the cell surface as determined by flow cytometry
analysis with either the anti-H-2Kb monoclonal antibody
HB41 or the monotypic anti-H-2 monoclonal antibody M1/42
and indirect immunofluorescence (Materials and Methods).
This strategy was used to select a population of cells with the
highest levels of expression of cell surface Kb antigen for use
as targets for the H-2b-restricted anti-AKR/Gross virus
CTL. The resultant SC.Kb population of cells had an in-
crease in Kb antigen expression that was significantly above
the value observed for untransfected SC-1 cells and close to
the levels of expression seen for the positive control SLi
(H-2b) tumor cells (Fig. 3). The population of SC.Kb cells
was reanalyzed after a period of weeks, confirming that Kb
antigen expression was stable. SL8 (H-2k) tumor cells were
negative for binding the anti-Db and the anti-Kb monoclonal
antibodies, as expected.
As previously mentioned, Green et al. (23) used monoclo-
nal antibodies specific for the Kb antigen or for the Db
antigen to determine that only the anti-Kb antibody could
prevent lysis by anti-AKR/Gross virus CTL of the appropri-
ate target cells. It was not known whether this was because
the Db antigen simply could not act as a restricting element
in this system under any circumstances or whether it did not
act as a restricting element because of the presence of the
dominant Kb antigen. We decided to analyze the class I
restriction elements for the anti-AKR/Gross virus CTL
further by transfecting SC-1 cells with a plasmid containing
the Db gene as described in Materials and Methods. Expres-
sion of Db antigen on SC.Db cells approached the Db
expression seen on SLi positive control cells, suggesting
that the SC.Db cells had sufficient levels of expression for
recognition by antiviral CTL (Fig. 3). Incidentally, the
monotypic M1/42 monoclonal antibody, with broad speci-
ficity for H-2 class I antigens, did not react with SC.Db cells,
VOL. 64, 1990 2611
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FIG. 3. SC-1 cells were transfected with the Kb gene or the Db gene as detailed in Materials and Methods. The transfected cells were sorted
and analyzed after sorting by flow cytometry. The antibodies used for the postsort analyses were HB41, specific for H-2Kb, and HB19 or
MCA169, specific for H-2Db. TMFI, Total mean fluorescence intensity (arbitrary units).
a finding that is consistent with the specificity for this
antibody published previously (57, 58).
Allogeneic CTL functional analysis of SC.Kb and SC.Db
cells. To determine whether the expression of Kb antigen on
the surface of the SC.Kb sorted cell population was sufficient
for efficient lysis by CTL, these cells were labeled with 51Cr
for use as targets against allogeneic anti-H-2b CTL generated
by stimulating spleen cells from DBA/2J (H-2d) responder
mice with irradiated spleen cells from C57BL/6J (H-2b) mice
(Materials and Methods). Representative data are shown in
Fig. 4. SC.Kb cells that had been sorted for optimal Kb
antigen expression were lysed substantially by the anti-H-2b
allogeneic CTL. The sorted SC.Db target cells were lysed by
the allogeneic CTL with an efficiency approaching that seen
for the SC.Kb cells. The use of untransfected SC-1 cells as
targets resulted in background levels of lysis, as expected.
The positive control SL1 tumor target cells of H-2b haplo-
type were efficiently lysed by the anti-H-2b CTL. YAC
(H-2a) cells were not lysed, indicating that cell lysis was due
to allogeneic CTL rather than to NK cells, and showing that
these CTL were specific for H-2b. These findings provide
evidence that the SC.Kb and the SC.Db cell populations are
efficient targets for allogeneic CTL and therefore should
have sufficient Kb and Db antigen expression, respectively,
to be lysed by antiviral CTL after infection with virus
isolates from various AKXL mice.
Infection of SC.Kb and SC.Db cells with EMV isolates from
AKXL mice. In order to analyze the ability of emv-11 versus
emv-14 viral antigens to serve as targets for anti-AKRIGross
virus CTL, the SC.Kb transfected cells were infected with
virus isolates (described above) from AKXL mice having the
various emv genotypes. After the infection was allowed to
spread laterally by extended cell culture, virus titers in the
EMV-infected SC.Kb lines were determined by the XC
plaque assay. emv-JJ-containing SC.Kb/9 or SC.Kb/21 cells
and emv-14-containing SC.KbI5 cells had equivalently high
viral titers (Fig. 5). The virus titers of these cells were
reconfirmed after a period of time to show that virus pro-
duction was stable. The data confirm that SC.Kb cells were
infected by virus isolated from the various AKXL mice.
Similar virus titers were shown for EMV-infected SC.Db
cells (data not shown).
Antiviral CTL lysis of EMV-infected SC.Kb and SC.Db
cells. SC.KbI5 cells were used as targets for H-2b-restricted
anti-AKR/Gross virus CTL lysis to determine whether emv-
14, upon infection into SC.Kb cells, continued to escape
recognition by antiviral CTL. Representative data are shown
in Fig. 6A and B. SC.KbI5 cells were not lysed by such CTL
significantly above the control values (obtained by using
effector cells not restimulated by antigen in vitro, i.e.,
unstimulated effector cells). In sharp contrast, SC.Kb/9 and
SC.Kb/21 target cells, both containing emv-JJ, were effi-
ciently recognized and lysed by antiviral CTL. These emv-
11+ target cells were lysed to a similar extent as SC.Kb cells
infected with AKR 623 virus, a cloned provirus derived from
an SC-1.Akv-1 congenic cell line (38). The two positive
control (H-2b, GCSA+) tumor cell targets SLi and EdG2
were lysed efficiently, and the variant cl.18.5 was lysed
poorly, as is usually seen for bulk anti-AKR/Gross virus
CTL specifically directed against these tumor cell targets
(16). The failure of effector cells to lyse YAC targets
confirmed that NK cells were not present. As expected,
relatively low levels of lysis of SC-1 target cells were
observed because they were neither H-2b nor emv+; SC.Kb
cells were poorly lysed because they were not emv+; and
SC-1/21 cells were poorly lysed because they were not H-2b.
These data show that the defect responsible for the previ-
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FIG. 4. Allogeneic CTL lysis of SC.Kb and SC.Db cells. SC.Kb cells and SC.Db cells were transfected with the Kb gene or the Db gene,
respectively, as given in Materials and Methods. Cells positive for class I Kb or Db antigen expression were G418 selected, sorted, and
analyzed with monoclonal antibodies and by flow cytometry as indicated in the legend to Fig. 3. The resultant SC.Kb and SC.Db cells were
then analyzed for their ability to function as target cells in a 51Cr release assay against allogeneic anti-H-2b CTL. Allogeneic anti_H-2b CTL
were generated by stimulating spleen cells from DBA/2J (H-2d) responder mice with irradiated spleen cells from C57BL/6J (H-2b) mice as
detailed in Materials and Methods. Unstimulated effector cells were used as negative controls. SL1 are H-2b Gross virus-positive tumor cells,
and YAC is a highly NK-sensitive target cell. The data for an effector-to-target cell (E:T) ratio of 100:1 are shown. Ratios of 20:1 and 4:1 were
also used, and the percent lysis (data not shown) was titrated as expected.
anti-AKR/Gross virus CTL is at the level of recognition
between virus-infected cell and effector CTL or pre-CTL
and that the mutation responsible for this defect is most
likely located within the emv-14 provirus.
Neither emv-11- nor emv-14-infected SC.Db cells were
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FIG. 5. Viral titers of infected SC.Kb cells. SC.Kb cells were
infected with virus isolated from various AKXL strains. After a
period of weeks, the infected SC.Kb cells were analyzed by the XC
plaque assay as detailed in Materials and Methods to titer the virus
expression. SC.Kb/9, SC.Kb/21, and SC.Kb/5 are SC.Kb cells in-
fected with virus isolated from AKXL-9, AKXL-21, and AKXL-5
mice, respectively.
This failure occurred despite the fact that SC.Db cells are
capable of being lysed by anti-H-2b allogeneic CTL (Fig. 4).
In the same experiment, SC.Kb/9, SC.Kb/21, and SC.Kb/623
targets were killed at levels similar to those found in other
experiments (data not shown), indicating that these particu-
lar bulk CTL were effective as usual against emv-11-asso-
ciated fibroblast targets. The results indicate that anti-AKR/
Gross virus CTL are unable to recognize these viral antigens
in the context of the Db class I antigen even when the
dominant Kb class I antigen is absent. This finding is in
contrast to work by others, who maintain that env antigens
recognized by anti-Gross virus CTL, raised by a somewhat
different sensitization protocol, are restricted significantly
by Db in addition to Kb (51).
It was important to confirm that the failure of anti-
AKR/Gross virus CTL to lyse SC.KbI5 cells was not due to
downregulation of the expression of the transfected class I
gene by emv-14 and not by emv-JJ. Others have shown that
MHC class I antigen expression can be regulated by virus
infection (reference 12, for example). When SC.Kb or SC.Db
cells were infected with virus isolated from emv-14+ mice,
the expression of Kb or Db antigen, respectively, was not
decreased (Fig. 3). In addition, SC.KbI5 cells were lysed by
anti-H-2b allogeneic CTL (DBA anti-C57BL/6, generated as
for Fig. 4) as efficiently as SC.Kb/9 cells. At an effector-
to-target cell ratio of 100:1, for example, the lysis of SC.Kb/5
and SC. Kb/9 target cells was 62 and 61%, respectively,
relative to 65% lysis of the positive control H-2b E&G2
tumor cells (data not shown). The lack of killing of YAC-1
(H-2a) target cells (4.5% lysis) in this particular experiment
indicated that the lysis was H-2b specific and due to alloge-
neic CTL rather than to NK cells. A decrease in MHC class
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FIG. 6. Antiviral CTL lysis of EMV-infected SC.Kb and SC.Db cells. SC.Kb and SC.Db cells infected with virus isolates from various
AKXL strains were analyzed for their ability to be lysed in a 51Cr release assay by anti-AKR/Gross virus CTL. Antiviral CTL were generated
by stimulating B.GV-primed C57CL/6J spleen cells in vitro with irradiated SL1 cells as detailed in Materials and Methods. The emv genotypes
of the infected SC.Kb and SC.Db cells are indicated along the abscissa. SC.Kb/623 and SC.Db/623 cells are SC.Kb or SC.Db cells, respectively,
infected with AKR 623 virus. SL1 and EcTG2 cells are H-2b Gross virus-positive control tumor cells. C1.18-5 serves as a negative control for
anti-AKR/Gross virus CTL. YAC is a highly NK-sensitive target cell. The effector-to-target cell (E:T) ratios of the data shown were 100:1.
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TABLE 1. Viral epitope expression of infected SC.Kb cellsa
Cells Antibody % Posi- TMFIc
gp7O analysis














SC.Kb/9 (emv-11, Anti-gp70O 93 551






SC.Kb/21 Anti-gp70a 91 542







SC.Kb Anti-glycosylated gag -3 -5
Anti-p12 -3 -9
SC.Kb/5 (emv-14) Anti-glycosylated gag 70 165
Anti-p12 71 183
SC.Kb/9 (emv-J1, Anti-glycosylated gag 70 150
emv-13) Anti-p12 72 164
SC.Kb/21 Anti-glycosylated gag 80 173
(emv-11) Anti-p12 82 192
a SC.Kb cells prepared as described in the legend to Fig. 4 and infected with
the various virus isolates prepared as described in Materials and Methods
were analyzed for their expression of gp7O antigen (representative data
shown) or for their expression of gag antigen (representative data shown) by
flow cytometry. The monoclonal antibodies are directed against the different
viral epitopes as described in Materials and Methods.
b Values were corrected by subtracting the values for the isotype controls
(Materials and Methods).
c TMFI = total mean fluorescence (arbitrary units).
I antigen expression due to emv-14 infection cannot there-
fore account for any defect seen in the ability of SC.KbI5
cells to be lysed by CTL.
Expression of virus antigens on virus-infected SC.Kb cells.
To further characterize viral antigen expression in the EMV-
infected SC.Kb cells, the cells were analyzed by flow cytom-
etry with a panel of antiviral antibodies. Cytofluorographic
data with monoclonal antibodies specific for seven different
epitopes on the envelope antigen gp7O and two gag determi-
nants are shown in Table 1. The results confirm that the cells
were infected and expressing significant levels of viral anti-
gen. The data were also used to look for differences in
expression between emv-11 and emv-14 that might correlate
with the failure of emv-14-infected cells to be recognized by
anti-AKR/Gross virus CTL. Surprisingly, there were no
significant differences in the pattern of expression for the
various epitopes analyzed when comparing SC.Kb/9 (emv-
11, emv-13) or SC.Kb/21 (emv-11) cells with SC.Kb/5 (emv-
14) cells by this approach (Table 1). Interestingly, the gp7Oc
epitope was not expressed to a significant extent on any of
the EMV-infected cells, despite the ability of the anti-gp7Oc
monoclonal antibody to react strongly with positive-control
SL1 tumor cells (data not shown). In other cytofluorographic
experiments, the expression of three monoclonal antibody-
defined epitopes on the p15(E) envelope antigen and the use
of four additional gag-specific antibodies demonstrated no
significant differences in expression between emv-JJ- and
emv-14-infected cells (data not shown). The data suggest that
if there is a mutation within the coding sequence of an
emv-14 gag- or env-derived viral antigen that correlates with
CTL dysfunction, it may be a point mutation, for example,
that is not detectable with these particular antibodies.
DISCUSSION
It was previously shown that spleen cells from emv-14+
AKXL-5 mice fail to stimulate an anti-AKR/Gross virus
CTL response in a mixed lymphocyte culture with primed
C57BL/6 responder spleen cells, whereas emv-ll+ AKXL
strains do stimulate a CTL response (21). One possible
explanation for this failure is that there is a mutation within
a coding sequence portion of the viral genome at a site
critical for CTL recognition. Such a mutation could allow
emv-14-positive tumor cells to avoid recognition and lysis by
antiviral CTL. This would represent one mechanism by
which tumors may escape cellular immunity and become
established. It was therefore of interest to analyze the
mechanism by which emv-14+ cells fail to be recognized by
anti-AKR/Gross virus CTL. It was important to first deter-
mine whether the mutation responsible for the failure of
AKXL-5 spleen cells to stimulate a response was within the
emv-14 proviral genome or whether the mutation was at
some other locus within the murine genome. It was also
important to determine whether the relevant mutation was at
the level of recognition between target cell and effector cell.
It is shown here that when virus isolated from the emv-14+
AKXL-5 strain is used to infect SC.Kb cells, the resultant
SC.KbI5 cells are productively infected (Fig. 5 and Table 1)
but continue to evade recognition and lysis by H-2b-re-
stricted anti-AKR/Gross virus CTL (Fig. 6). Yet in a parallel
positive-control experiment, emv-l I+ SC.Kb/21 target cells
were lysed by these antiviral CTL, indicating that there is
nothing inherent about EMV-infected SC.Kb cells that
would prevent them from being recognized and lysed effi-
ciently by anti-AKR/Gross virus CTL. Overall, the data
indicate that the mutation responsible for CTL dysfunction
is at the level of recognition between target cell and effector
cell and is almost certainly within the emv-14 proviral
genome, since the resistance of emv-14+ cells to antiviral
CTL was maintained upon isolation of virus from AKXL-5
cells and infection into SC.Kb cells. The fact that the emv-14
provirus has reintegrated into different loci within the murine
genome in SC.Kb/5 cells relative to AKXL-5 cells (Southern
data not shown) is consistent with the mutation's being
within the emv-14 provirus and unaffected by flanking mu-
rine sequences.
The facts that AKXL-5 mice are viremic and that virus
message and cell surface antigens are expressed at levels
similar to those for emv-JJ (Fig. 1 and 2, Table 1) indicate
that emv-14 is expression competent and has a functional life
cycle. The relative titers for AKXL-5 and AKXL-16 mice, as
shown in Fig. 2, are especially important, since anti-AKRI
Gross virus CTL were stimulated by emv-J1-containing
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AKXL-16 spleen cells. These data, along with the RNA and
antigen quantitations, support the hypothesis that emv-14
virus expression is not quantitatively limiting the CTL
recognition process.
Green and Rich (unpublished) have shown that when
AKXL-5 (emv-14+) spleen cells are first treated with IUdR,
in the presence of lipopolysaccharide to stimulate incorpo-
ration of IUdR into DNA, and then used to stimulate an
antiviral CTL response by primed C57BL/6 spleen cells,
anti-AKR/Gross virus CTL still are not stimulated. This
finding, along with the data presented here showing that
emv-14 is expression competent, is consistent with the
relevant mutation's being within the coding sequence of an
expressed viral antigen critical for CTL recognition and not
at a regulatory site that may act to repress expression.
It would seem logical that an envelope antigen, especially
gp70, might be the target for CTL recognition and function
since this antigen is displayed on the cell surface and since
envelope antigens are recognized by and stimulate the
proliferation of antiviral CTL in other retroviral systems (for
example, see references 11 and 67). Alternatively, other
retroviral antigens may be targets for the CTL antigen
receptor. It has even been shown that CTL specific for the
human immunodeficiency virus (HIV) pol gene product,
reverse transcriptase, were found in blood samples from
HIV-1-seropositive individuals (68). This finding occurs de-
spite the fact that reverse transcriptase is normally thought
to reside within the virion in association with the RNA
genome, and may be due to viral antigen processing and
presentation in association with MHC antigen. In fact, there
are now numerous examples of viral antigens that are
localized intracellularly and yet are recognized by virus-
specific CTL. Specific examples include the influenza virus
nucleoprotein (65, 66) and viral polymerases (4), simian virus
40 T antigen (44, 63), murine cytomegalovirus immediate-
early regulatory protein (34), human cytomegalovirus 72-
kilodalton immediate-early protein (5), lymphochoriomenin-
gitis virus nucleoprotein (25), and herpes simplex virus
immediate-early proteins (41). In some cases it has been
confirmed that these virus antigens are serologically unde-
tectable on the cell surface (for example, see reference 41).
In some cases virus antigens are known to be largely
localized in the nucleus but are detectable at the cell surface
as determined by the inhibition of effector cell activity by
virus antigen-specific antibody (for example, see references
7 and 48). These findings are compatible with the hypothesis
that a processed peptide fragment bound to its MHC restric-
tion element is on the cell surface and is recognized by
antiviral CTL, but may or may not be recognizable by
virus-specific antibodies. This is understandable in light of
analyses by Grey and by Berzofsky of peptides bound to
MHC molecules having a molecular weight range of 2,000 to
10,000 (discussed in reference 42). These data indicate that
peptides can range from 10 to 20 amino acids in size to a
much larger size at which parts of the peptide are "spilling
over" the side of the MHC molecule. The presence of these
larger MHC-bound viral peptides may account for the ability
of anti-simian virus 40 T antigen monoclonal antibody (48) or
anti-human cytomegalovirus nuclear inclusion body protein
antibody (7) to block the lysis of virus-positive or virus-
coated target cells, respectively, by anti-virus-specific CTL.
This is an alternative hypothesis to the suggestion that cell
degradation due to viral pathogenesis may account for the
access of antiviral CTL to internal antigens.
There is evidence, however, that it is the gp7O envelope
antigen that is the major target for anti-AKR/Gross virus
CTL. Altered expression of the gp7O envelope antigen of two
variant subclones, cl.18-5 and cl.18-12, derived from a
CTL-susceptible tumor cell line of AKR.H-2b origin, corre-
late with the failure of these cells to be lysed efficiently by
anti-AKR/Gross virus bulk CTL. Treatment of these variant
subclones with IUdR to induce the expression of endoge-
nous latent EMV restores the expression of gp7O epitopes
and the susceptibility of these cells to lysis by anti-AKR/
Gross virus CTL (40). In addition, when env-defective
cl.18-5 is used to stimulate anti-AKR/Gross virus CTL, the
lysis of tumor or fibroblast target cells that are otherwise
lysed efficiently by SL1- or EBG2-stimulated CTL drops
dramatically (data not shown). These findings suggest that
the majority of the bulk CTL used here are env specific.
These data are in contrast to data by others, who maintain
that anti-AKR/Gross virus CTL recognize both gag and env
gene products with comparable intensities (51, 52). It was
therefore of great interest to determine whether the gag or
especially the env antigen expression profile for emv-14+
SC.Kb/5 cells was different from that for emv-11' SC.Kb/21
cells. Table 1 shows that there are no significant differences
in antigen profile as analyzed by antiviral monoclonal anti-
bodies and flow cytometry. These results were intriguing
since the cl.18-5 and cl.18-12 variant subclones mentioned
above showed large differences in the expression of gp7O
epitopes relative to the AKR.H-2b SLi parental line. The
data indicate that if gp7O, or one of the other viral antigens
analyzed by flow cytometry, is the target for CTL recogni-
tion against emv-14+ cells, then there must be a mutation,
perhaps a point mutation or a few point mutations or a small
insertion or deletion, that is responsible for the loss of CTL
function but is undetectable with the antibody reagents
available for analysis.
It is commonly thought that viral antigens provide multiple
determinants for CTL stimulation. How then could a small
mutation that is not detectable by antibody analysis be
responsible for abrogating a CTL response? There is prece-
dence in the literature for the recognition of a limited number
of immunodominant epitopes by antiviral CTL. For exam-
ple, a major population of murine influenza virus A-specific
CTL recognize the viral nucleoprotein (64); these investiga-
tors then determined via deletion mutant analysis of the NP
gene that Db-restricted polyclonal CTL are predominantly
directed at a 59-amino-acid region of NP. The majority of
CTL against lymphocytic choriomeningitis virus glycopro-
tein (GP) recognize targets expressing only a 22-amino-acid
region (30, 45). For the HIV gpl60env glycoprotein, the use
of overlapping peptides in a vaccinia virus expression sys-
tem revealed that a single 15-residue site was immunodom-
inant for CTL recognition in responder H-2d mice (61). In
fact, the same group recently synthesized two 15-mer pep-
tides derived from this immunodominant region and based
on two different HIV-1 isolates. The peptides differed in 6 of
15 residues, but the reciprocal exchange of only one of the
hypervariable residues was sufficient to interchange the
specificities of isolate-specific CTL (62). It is also possible
that a point mutation, or small insertion or deletion, within a
coding region of the virus may cause a conformational
change which destroys more than one determinant involved
in CTL recognition. A mutation within overlapping epitopes
would also affect more than one determinant. Finally, be-
cause the EMVs are carried endogenously as proviruses in
the murine germ line, there may be fewer EMV determinants
recognized by CTL because of exposure of thymic cells to
similar C57BL/6 proviral determinants. That is, selective
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pressures like those acting to induce tolerance may be
occurring.
Thus, in the C57BL/6 system, it is possible that a small
coding sequence mutation in the emv-14 virus is responsible
for the failure of emv-14+ SC.Kb/5 cells to be lysed by
anti-AKR/Gross virus CTL. In light of the possibility that
retroviruses such as HIV may use hypervariable env regions
to escape cellular immunity (see references 61 and 62, for
example), it will be interesting to further define the nature of
this mutation. It is less clear whether these findings will hold
in other strains, especially high leukemic strains such as
AKR/J. Although this paper deals with N-ecotropic provi-
ruses from AKRIJ mice, we and others have noticed a
number of differences in the ability of strains of the H-2b and
H-2k haplotypes to mount a response against AKR-derived
leukemic viruses and the tumors they induce. Both AKRIJ
(H-2k) and AKR.H-2b mice are nonresponders to N-ecotro-
pic proviral determinants because their immune system has
seen the virus starting from before birth (e.g., reference 37).
The functional immunogenicity of EMVs would therefore be
difficult to study within the AKR/J system. In addition, H-2k
haplotype mice (most notably C57BL/6.H-2k [19]) are poor
responders in general for eliciting anti-AKR/Gross virus
CTL. Others have shown that the majority of leukemias
from AKR mice are poorly immunogenic in the AKR strain
(56). In the same study, one unusual leukemia, 369, was
highly immunogenic and induced CTL which killed 369 cells
in vitro; in contrast, most of the AKR effector cells derived
by immunizing and restimulating in vitro with the various
immunizing leukemias failed to lyse the immunizing tumor
cells. In addition to a poor anti-AKR/Gross virus CTL
response on the part of AKR mice, EMVs have high
mutation rates. These factors together are likely to contrib-
ute significantly to the exceptionally high incidence of leu-
kemia in AKR mice.
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